Reduction in [D-Ala2, NMePhe4, Gly-ol 5]Enkephalin-Induced Peripheral Antinociception in Diabetic Rats: The Role of the L-Arginine/Nitric Oxide/Cyclic Guanosine Monophosphate Pathway

Anesthesia and Analgesia

Volumn 98, Issue 1, 2004, Pages 185-192

  Tasatargil, Arda ^a   Sadan, Gulay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC GMP; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FORMALDEHYDE; LINSIDOMINE; METHYLENE BLUE; N5 (1 IMINOETHYL)ORNITHINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; STREPTOZOCIN;

AGITATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; INFLAMMATION; MALE; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT;

EID: 0347363655     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000093250.59364.EB     Document Type: Article

References (64)

1. Millan MJ. Multiple opioid systems and pain. Pain 1986;27:303-47.
2. Pasternak GW. Multiple morphine and enkephalin receptors and the relief of pain. JAMA 1988;259:1362-7.
3. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685-90.
4. Ferreira SH, Nakamura M. II. Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 1979;18:191-200.
5. Ferreira SH, Nakamura M. III. Prostaglandin hyperalgesia: relevance of the peripheral effect for the analgesic action of opioidantagonists. Prostaglandins 1979;18:201-8.
6. Ferreira SH, Molina N, Vettore O. Prostaglandin hyperalgesia. V. A peripheral analgesic receptor for opiates. Prostaglandins 1982;23:53-60.
7. Levine JD, Taiwo YO. Involvement of the mu-opiate receptor in peripheral analgesia. Neuroscience 1989;32:571-5.
8. Stein C, Millan MJ, Shippenberg TS, et al. Peripheral opioid receptors mediating antinociception in inflammation: evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989;248:1269-75.
9. Dennis SG, Melzack R. Pain modulation by 5-hydroxytryptaminergic agents and morphine as measured by 3 pain tests. Exp Neurol 1980;69:260-70.
10. Ferreira SH, Duarte ID, Lorenzetti BB. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 1991;201:121-2.
11. Duarte ID, Santos IR, Lorenzetti BB, et al. Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 1992;217:225-7.
12. Deguchi T. Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. J Biol Chem 1977;252:7617-9.
13. Nozaki-Taguchi N, Yamamoto T. The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg 1998;86:367-73.
14. 2+ dependent process. Prostaglandins 1979;18:179-90.
15. Aley KO, Levine JD. Different mechanisms mediate development and expression of tolerance and dependence for peripheral μ-opioid antinociception in rat. J Neurosci 1997;17:8018-23.
16. Aley KO, Levine JD. Dissociation of tolerance and dependence for opioid peripheral antinociception in rats. J Neurosci 1997;17:3907-12.
17. Kamei J, Ohhashi Y, Aoki T, et al. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists. Brain Res 1992;571:199-203.
18. Simon GS, Dewey WL. Narcotics and diabetes. I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther 1981;218:318-23.
19. Ozdem SS, Sadan G, Usta C, et al. The effect of experimental diabetes on cholinergic neurotransmission in rat trachea: role of nitric oxide. Eur J Pharmacol 2000;387:321-7.
20. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977;4:161-74.
21. Granados-Soto V, Rufino MO, Lopes LD, et al. Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur J Pharmacol 1997;340:177-80.
22. Duarte IDG, Lorenzetti BB, Ferreira SH. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol 1990;186:289-93.
23. Hong Y, Abbott FV. Peripheral opioid modulation of pain and inflammation in the formalin test. Eur J Pharmacol 1995;277:21-8.
24. Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993;76:182-91.
25. DeHaven-Hudkins DL, Burgos LC, Cassel JA, et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999;289:494-502.
26. Oluyomi AO, Hart SL, Smith TW. Differential antinociceptive effects of morphine and methylmorphine in the formalin test. Pain 1992;49:415-8.
27. Hunskaar S, Hole K. The formalin test: dissociation between inflammatory and non-inflammatory pain. Pain 1987;30:103-14.
28. Dickenson AH, Sullivan AF. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: different response to an intrathecal opiate administered pre or post formalin. Pain 1987;30:349-60.
29. Taddese A, Nah S, McCleskey EW. Selective opioid inhibition of small nociceptive neurons. Science 1995;270:1366-8.
30. Cooper BY, Vierck CJ Jr, Yeomans DC. Selective reduction of second pain sensations by systemic morphine in humans. Pain 1986;24:93-116.
31. Torebjork HE, Hallin RG. Perceptual changes accompanying controlled preferential blocking of A and C fibre responses in intact human skin nerves. Exp Brain Res 1973;16:321-32.
32. Taiwo YO, Heller PH, Levine JD. Mediation of serotonin hyperalgesia by the cAMP second messenger system. Neuroscience 1992;48:479-83.
33. + channels in cultured vascular smooth muscle cells. Circ Res 1994;74:471-6.
34. Murphy ME, Brayden JE. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 1995;486:47-58.
35. + channels in cGMP-mediated pial artery vasodilation. Am J Physiol 1996;270: H423-6.
36. Zhu P, Beny JL, Flammer J, et al. Relaxation by bradykinin in porcine ciliary artery: role of nitric oxide and K(+)-channels. Invest Ophthalmol Vis Sci 1997;38:1761-7.
37. Carrier GO, Fuchs LC, Winecoff AP, et al. Nitrovasodilators relax mesenteric microvessels by cGMP-induced stimulation of Ca-activated K channels. Am J Physiol 1997;273:H76-84.
38. Soares AC, Leite R, Tatsuo MA, Duarte ID. Activation of ATP-sensitive K(+) channels: mechanism of peripheral antinociceptive action of the nitric oxide donor, sodium nitroprusside. Eur J Pharmacol 2000;400:67-71.
39. Ahlgren SC, Levine JD. Mechanical hyperalgesia in streptozotocin-induced diabetic rats. Neuroscience 1993;52:1049-55.
40. Sasaki T, Yasuda H, Maeda K, Kikkawa R. Hyperalgesia and decreased neuronal nitric oxide synthase in diabetic rats. Neuroreport 1998;9:243-7.
41. McFadzean I. The ionic mechanisms underlying opioid actions. Neuropeptides 1988;11:173-80.
42. Smith FL, Stevens DL. Calcium modulation of morphine analgesia: role of calcium channels and intracellular pool calcium. J Pharmacol Exp Ther 1995;272:290-9.
43. Reddy PM, Shantanu S, Shewade DG, Ramaswamy S. Effect of ATP sensitive potassium channel modifiers on antinociceptive effect of metoclopramide. Indian J Exp Biol 2001;39:476-8.
44. Arguelles CF, Torres-Lopez JE, Granados-Soto V. Peripheral antinociceptive action of morphine and the synergistic interaction with lamotrigine. Anesthesiology 2002;96:921-5.
45. Dogrul A, Zagli U, Tulunay FC. The role of T-type calcium channels in morphine analgesia, development of antinociceptive tolerance and dependence to morphine, and morphine abstinence syndrome. Life Sci 2002;71:725-34.
46. Granados-Soto V, Argüelles CF, Ortiz MI. The peripheral antinociceptive effect of resveratrol is associated with activation of potassium channels. Neuropharmacology 2002;43:917-23.
47. Quasthoff S, Grosskreutz J, Schroder JM, et al. Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibers of biopsied human sural nerve. Neuroscience 1995;69:955-65.
48. Grosskreutz J, Quasthoff S, Kuhn M, Grafe P. Capsaicin blocks tetrodotoxin-resistant sodium potentials and calcium potentials in unmyelinated C fibers of biopsied human sural nerve in vitro. Neurosci Lett 1996;208:49-52.
49. + currents and inflammatory hyperalgesia. Proc Natl Acad Sci U S A 1999;96:7645-9.
50. Hirade M, Yasuda H, Omatsu-Kanbe M, et al. Tetrodotoxin-resistant sodium channels of dorsal root ganglion neurons are readily activated in diabetic rats. Neuroscience 1999;90:933-9.
51. 2+ current in the action potentials of nociceptive sensory neurons. J Neurosci 2002;22:10277-90.
52. Voitenko NV, Kostyuk EP, Kruglikov IA, Kostyuk PG. Changes in calcium signalling in dorsal horn neurons in rats with streptozotocin-induced diabetes. Neuroscience 1999;94:887-90.
53. Hall KE, Sima AA, Wiley JW. Voltage-dependent calcium currents are enhanced in dorsal root ganglion neurones from the Bio Bred/Worchester diabetic rat. J Physiol 1995;486:313-22.
54. Kostyuk E, Pronchuk N, Shmigol A. Calcium signal prolongation in sensory neurones of mice with experimental diabetes. Neuroreport 1995;6:1010-2.
55. 2+ channels in attenuated morphine antinociception in streptozotocin-diabetic rats. Eur J Pharmacol 2002;435:187-94.
56. + channels. Br J Pharmacol 2000;129:110-4.
57. Ohsawa M, Kamei J. Possible involvement of protein kinase C in the attenuation of [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced antinociception in diabetic mice. Eur J Pharmacol 1997;339:27-31.
58. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992;89:11059-63.
59. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. J Clin Invest 1989;83:1667-75.
60. Numann R, Catterall WA, Scheuer T. Functional modulation of brain sodium channels by protein kinase C phosphorylation. Science 1991;254:115-8.
61. + channel α subunit by cAMP-dependent protein kinase end phosphoprotein phosphatases. J Biol Chem 1993;268:355-62.
62. Li M, West JW, Numann R, et al. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 1993;261:1439-42.
63. Kamei J, Iguchi E, Sasaki M, et al. Modification of the fenvalerate-induced nociceptive response in mice by diabetes. Brain Res 2002;948:17-23.
64. Narita M, Ohsawa M, Mizoguchi H, et al. Pretreatment with protein kinase C activator phorbol 12,13-dibutyrate attenuates the antinociception induced by μ- but not ε-opioid receptor agonist in the mouse. Neuroscience 1996;76:291-8.